Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma
Authors:
- N. L. BerinsteinNBN. L. Berinstein
- A. J. Grillo-LopezAGA. J. Grillo-Lopez
- C. A. WhiteCWC. A. White
- I. Bence-BrucklerIBI. Bence-Bruckler
- J. RosenbergJRJ. Rosenberg
- P. McLaughlinPMP. McLaughlin
- D. ShenDSD. Shen
Open Access
- 1 September 1998
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 9 (9) , 995-1001
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.Journal of Clinical Oncology, 1997
- Immunosuppressive Toxicity of CAMPATH®1H Monoclonal Antibody in the Treatment of Patients with Recurrent Low Grade LymphomaLeukemia & Lymphoma, 1996
- CD19 Antigen in Leukemia and Lymphoma Diagnosis and ImmunotherapyLeukemia & Lymphoma, 1995
- Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow SupportNew England Journal of Medicine, 1993
- Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) AntibodyNew England Journal of Medicine, 1993
- Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibodyCancer Immunology, Immunotherapy, 1991
- Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.Proceedings of the National Academy of Sciences, 1989
- A phase 1a clinical trial of LYM‐1 monoclonal antibody serotherapy in patients with refractory b cell malignanciesHematological Oncology, 1989
- REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1HThe Lancet, 1988
- Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host diseaseHuman Immunology, 1984